We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+3.27%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$259M
AUM Growth
+$35.4M
Cap. Flow
+$44.7M
Cap. Flow %
17.29%
Top 10 Hldgs %
86.99%
Holding
34
New
6
Increased
4
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$39M
2
ONC
BeOne Medicines Ltd
ONC
+$11.2M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10.5M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$9.18M
5
MDCO
Medicines Co
MDCO
+$4.55M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.25M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$7.97M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$5.28M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$4.96M
5
HRTX icon
Heron Therapeutics
HRTX
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 80.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$49.1M 18.99%
1,028,763
+729,007
+243% +$39M
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$37.8M 14.6%
850,000
-150,000
-15% -$5.28M
MDCO
3
DELISTED
Medicines Co
MDCO
$28.1M 10.87%
828,198
+128,198
+18% +$4.55M
ONC
4
BeOne Medicines Ltd
ONC
$32.8B
$25.8M 9.98%
850,000
+356,370
+72% +$11.2M
MDCO
5
CALL
DELISTED
Medicines Co
MDCO
$21.3M 8.24%
627,400
+77,600
+14% +$2.75M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$19.8M 7.65%
705,159
– –
NGNE icon
7
Neurogene
NGNE
$656M
$14.5M 5.61%
43,888
– –
INCY icon
8
Incyte
INCY
$24.2B
$10M 3.88%
100,000
– –
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$27.5B
$9.36M 3.62%
+250,000
New +$10.5M
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$9.18M 3.55%
+75,000
New +$9.18M
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$5.28M 2.04%
100,000
-132,600
-57% -$7.97M
TSRO
12
DELISTED
TESARO, Inc.
TSRO
$4.71M 1.82%
35,000
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.6M 1.39%
757,935
– –
KURA icon
14
Kura Oncology
KURA
$800M
$3.15M 1.22%
533,251
– –
SBBP
15
DELISTED
Strongbridge Biopharma plc.
SBBP
$2.26M 0.87%
+940,000
New +$3.83M
VIRX
16
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.9M 0.74%
+15,000
New +$2.09M
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
$1.76M 0.68%
200,000
– –
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.69B
$1.68M 0.65%
234,220
– –
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.61M 0.62%
4,611
– –
ALDX icon
20
Aldeyra Therapeutics
ALDX
$92.9M
$1.56M 0.6%
291,230
– –
NBRV
21
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.05M 0.41%
707
– –
ARDM
22
DELISTED
Aradigm Corp Common Stock
ARDM
$1.02M 0.39%
634,708
-295,805
-32% -$1.3M
AKTX
23
Akari Therapeutics
AKTX
$13.8M
$985K 0.38%
175
– –
BLPH
24
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$966K 0.37%
+123,810
New +$1.72M
TRAW icon
25
Traws Pharma
TRAW
$6.85M
$718K 0.28%
56
– –
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Boxer Capital held 34 positions worth $259M, up 16% from $223M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Boxer Capital deployed $44.7M of net new capital in Q4 2016, opening 6 new positions and adding to 4 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 250,000 shares worth $9.36M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 76% a quarter earlier.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $7.97M trimmed.

  • Boxer Capital's largest Q4 2016 buy was Alnylam Pharmaceuticals: 250,000 shares worth $9.36M.
  • Boxer Capital added most to AveXis, Inc. Common Stock in Q4 2016, an estimated $39M increase.
  • Boxer Capital's biggest Q4 2016 reduction was Seagen Inc. Common Stock, cutting an estimated $7.97M.
  • Boxer Capital fully exited BioMarin Pharmaceuticals in Q4 2016, selling an estimated $9.25M.
  • Boxer Capital's ten largest holdings make up 87% of its $259M portfolio in Q4 2016.
  • Boxer Capital opened 6 new positions and closed 6 in Q4 2016.
  • Boxer Capital's portfolio value rose 16% quarter-over-quarter to $259M.

Based on Boxer Capital's 13F filing for Q4 2016, filed 14 Feb 2017.